Diagnostic accuracy of serum 1,3-β-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: Systematic review and meta-analysis

Journal of Clinical Microbiology

Volumn 50, Issue 1, 2012, Pages 7-15

  Onishi, Akira ^a   Sugiyama, Daisuke ^a   Kogata, Yoshinori ^a   Saegusa, Jun ^a   Sugimoto, Takeshi ^a   Kawano, Seiji ^a   Morinobu, Akio ^a   Nishimura, Kunihiro ^a,b   Kumagaia, Shunichi ^a,c  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c Shinko Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1,3 GLUCAN;

AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS; BLOOD ANALYSIS; CANDIDA; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LUNG LAVAGE; MEDLINE; MICROSCOPY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; SYSTEMATIC REVIEW;

ASPERGILLOSIS; BETA-GLUCANS; CANDIDIASIS, INVASIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERUM;

PNEUMOCYSTIS JIROVECII;

EID: 84555188028     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05267-11     Document Type: Article

References (62)

1. Acosta J, et al. 2011. A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1→3)-beta-D-glucan chromogenic assay in serum samples. Clin. Microbiol. Infect. 17:1053-1060.
2. Akamatsu N, Sugawara Y, Kaneko J, Tamura S, Makuuchi M. 2007. Preemptive treatment of fungal infection based on plasma (1→3)beta-D-glucan levels after liver transplantation. Infection 35:346-351. (Pubitemid 47502349)
3. Alam FF, Mustafa AS, Khan ZU. 2007. Comparative evaluation of (1,3)-beta-D-glucan, mannan and anti-mannan antibodies, and candida species-specific snPCR in patients with candidemia. BMC Infect. Dis. 7:103.
4. Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. 2010. The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J. Clin. Microbiol. 48:4083-4088.
5. Ascioglu S, et al. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14. (Pubitemid 33152659)
6. Avina-Zubieta JA, et al. 2008. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 59:1690-1697.
7. Bossuyt PM, et al. 2003. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 326:41-44. (Pubitemid 36110721)
8. Carmona EM, Limper AH. 2011. Update on the diagnosis and treatment of pneumocystis pneumonia. Ther. Adv. Respir. Dis. 5:41-59.
9. Cochran WG. 1954. The combination of estimates from different experiments. Biometrics 10:101-129.
10. Deeks J. 2001. Systematic reviews of evaluations of diagnostic and screening tests, p 248-282. In Egger M, Davey Smith G, Altman D (ed), Systematic reviews in health care: meta-analysis in context, 2nd ed. BMJ, London, United Kingdom.
11. De Pauw B, et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin. Infect. Dis. 46:1813-1821.
12. Desmet S, et al. 2009. Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J. Clin. Microbiol. 47:3871-3874.
13. Egger M, Davey Smith G, Schneider M, Minder C. 1997. Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629-634. (Pubitemid 27387172)
14. Fujita S, Takamura T, Nagahara M, Hashimoto T. 2006. Evaluation of a newly developed down-flow immunoassay for detection of serum mannan antigens in patients with candidaemia. J. Med. Microbiol. 55:537-543.
15. Fukuda T, et al. 2003. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102:827-833. (Pubitemid 36917771)
16. Hachem RY, et al. 2009. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J. Clin. Microbiol. 47:129-133.
17. Held J, Koch M, Reischl U, Danner T, Serr A. 2011. Serum (1→3)-beta-D-glucan measurement as early indicator for Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin. Microbiol. Infect. 17:595-602.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. 2003. Measuring inconsistency in meta-analyses. BMJ 327:557-560. (Pubitemid 37088507)
19. Hirata Y, et al. 2010. Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies. Leuk. Lymphoma 51:853-859.
20. Horiguchi Y. 2004. The performance of (1, 3)-beta-D-glucan and aspergillus galactomannan measurement for early diagnosis of invasive aspergillosis in patients with hematological diseases. Kansenshogaku Zasshi 78:566-573.
21. Irwig L, et al. 1994. Guidelines for meta-analyses evaluating diagnostic tests. Ann. Intern. Med. 120:667-676. (Pubitemid 24106180)
22. Kami M, et al. 2000. Computed tomographic scan of the chest, latex agglutination test and plasma (1-3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica 85:745-752. (Pubitemid 30617109)
23. Karageorgopoulos DE, et al. 2011. Beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin. Infect. Dis. 52:750-770.
24. Kawazu M, et al. 2004. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J. Clin. Microbiol. 42:2733-2741. (Pubitemid 38747529)
25. Kedzierska A, Kochan P, Pietrzyk A, Kedzierska J. 2007. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1→3)-beta-D-glucan antigens. Eur. J. Clin. Microbiol. Infect. Dis. 26:755-766. (Pubitemid 47573385)
26. Kondori N, Edebo L, Mattsby-Baltzer I. 2004. Circulating beta (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis. Clin. Diagn. Lab. Immunol. 11:344-350. (Pubitemid 38380816)
27. Koo S, Bryar JM, Page JH, Baden LR, Marty FM. 2009. Diagnostic performance of the (1→3)-beta-D-glucan assay for invasive fungal disease. Clin. Infect. Dis. 49:1650-1659.
28. Leeflang MM, et al. 2008. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst. Rev. 2008:CD007394.
29. Leon C, et al. 2009. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit. Care Med. 37:1624-1633.
30. Lijmer JG, et al. 1999. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282:1061-1066. (Pubitemid 29436454)
31. Limper AH, Offord KP, Smith TF, Martin WJ, II. 1989. Pneumocystis carinii pneumonia: differences in lung parasite number and inflammation in patients with and without AIDS. Am. Rev. Respir. Dis. 140:1204-1209. (Pubitemid 19276197)
32. Liu F, et al. 2009. Diagnostic value of plasma (1, 3)-beta-D glucan assay for invasive fungal infections in patients with hematological disorders. Zhongguo Shi Yan Xue Ye Xue Za Zhi 17:1043-1046.
33. Lu PH, Zhao BL, Shi Y, Wen YT. 2007. The diagnostic value of detecting plasma 1, 3-beta-D-glucan for invasive fungal infections. Zhonghua Jie He He Hu Xi Za Zhi 30:31-34.
34. Lunel FM, et al. 2009. Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. Diagn. Microbiol. Infect. Dis. 64:408-415.
35. Mansharamani NG, Garland R, Delaney D, Koziel H. 2000. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 118:704-711.
36. McLintock LA, Jones BL. 2004. Advances in the molecular and serological diagnosis of invasive fungal infection in haemato-oncology patients. Br. J. Haematol. 126:289-297. (Pubitemid 39005708)
37. Midgette AS, Stukel TA, Littenberg B. 1993. A meta-analytic method for summarizing diagnostic test performances: receiver-operatingcharacteristic- summary point estimates. Med. Decis. Making 13:253-257. (Pubitemid 23199345)
38. Mitsutake K, et al. 1996. Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia. J. Clin. Microbiol. 34:1918-1921. (Pubitemid 26239223)
39. Mori T, et al. 1997. Evaluation of plasma (1→3)-beta-D-glucan measurement by the kinetic turbidimetric limulus test, for the clinical diagnosis of mycotic infections. Eur. J. Clin. Chem. Clin. Biochem. 35:553-560. (Pubitemid 27351204)
40. Moro H, et al. 2003. Comparison of four diagnostic methods using clinical blood by measuring (1→3)-beta-D-glucan. Kansenshogaku Zasshi 77:227-234.
41. Moses LE, Shapiro D, Littenberg B. 1993. Combining independent studies of a diagnostic test into a summary roc curve: data-analytic approaches and some additional considerations. Stat. Med. 12:1293-1316. (Pubitemid 23230833)
42. Nakamura H, et al. 2009. Clinical utility of serum beta-D-glucan and kl-6 levels in Pneumocystis jirovecii pneumonia. Intern. Med. 48:195-202.
43. Obayashi T, et al. 1995. Plasma (1→3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345:17-20.
44. Obayashi T, Negishi K, Suzuki T, Funata N. 2008. Reappraisal of the serum (1→3)-beta-D-glucan assay for the diagnosis of invasive fungal infections-a study based on autopsy cases from 6 years. Clin. Infect. Dis. 46:1864-1870.
45. Odabasi Z, et al. 2004. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis. 39:199-205. (Pubitemid 38971490)
46. Ostrosky-Zeichner L, et al. 2005. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 41:654-659. (Pubitemid 41170353)
47. Pazos C, Ponton J, Del Palacio A. 2005. Contribution of (1→3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J. Clin. Microbiol. 43:299-305. (Pubitemid 40096315)
48. Persat F, et al. 2008. Contribution of the (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J. Clin. Microbiol. 46:1009-1013. (Pubitemid 351379994)
49. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. 2005. Evaluation of a (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J. Clin. Microbiol. 43:5957-5962. (Pubitemid 43100644)
50. Presterl E, et al. 2009. Invasive fungal infections and (1,3)-beta-D-glucan serum concentrations in long-term intensive care patients. Int. J. Infect. Dis. 13:707-712.
51. Racil Z, et al. 2009. Detection of 1,3-beta-D glucan for diagnosis of invasive fungal infections in hematooncological patients: usefulness for screening of invasive mycosis and for confirmation of galactomannan positive results. Klin. Mikrobiol. Infekc. Lek. 15:48-57.
52. Reitsma JB, et al. 2009. Chapter 9: assessing methodological quality. In Deeks JJ, Bossuyt PM, GatsonisC(ed). Cochrane handbook for systematic reviews of diagnostic test accuracy version 1.0.0. The Cochrane Collaboration. http://srdta.cochrane.org/.
53. Rutjes AW, et al. 2006. Evidence of bias and variation in diagnostic accuracy studies. CMAJ 174:469-476.
54. Senn L, et al. 2008. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin. Infect. Dis. 46:878-885. (Pubitemid 351417190)
55. Sutton A, Jones D, Sheldon T, Song F. 2000. Methods for meta-analysis in medical research. Wiley, London, United Kingdom.
56. Tasaka S, et al. 2007. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 131:1173-1180. (Pubitemid 46608722)
57. Watanabe T, et al. 2009. Serum (1→3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of pneumocystis pneumonia in patients with aids. Clin. Infect. Dis. 49:1128-1131.
58. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. 2003. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews.BMCMed. Res. Methodol. 3:25.
59. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. 1996. (1→3) Beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin. Diagn. Lab Immunol. 3:197-199. (Pubitemid 26103756)
60. Yoshida K, et al. 2006. Clinical usefulness of the (1→3)-beta-D- glucan measurement kit using the improved alkaline pretreatment method - comparison with conventional method. Kansenshogaku Zasshi 80:701-705.
61. Yu J, Li RY, Gao LJ, Lu QY, Wang XH. 2010. Utility of galactomannan enzyme immunoassay and (1,3)beta-D-glucan assay in invasive fungal infection. Zhonghua Yi Xue Za Zhi 90:371-374.
62. Zhao L, et al. 2009. Value of plasma beta-glucan in early diagnosis of invasive fungal infection in children. Zhongguo Dang Dai Er Ke Za Zhi 11:905-908.